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Abstract The multi-functional protein calreticulin (CRT) is
normally found within the lumen of the endoplasmic reticulum
(ER). However, some of its proposed functions require it to be
located within the nucleus, where its presence is contentious. We
have investigated this in live COS7, HeLa and LM(TK
3
) cells
using green fluorescent protein (GFP)-fusion proteins. GFP-
CRT, and GFP, with an ER signal peptide and a KDEL
sequence (ER-GFP), were localised to the ER. In addition, GFP-
CRT was located in the nucleus of all the cell types at low levels.
The higher levels of nuclear fluorescence in LM(TK
3
) and HeLa
cells suggested that glucocorticoid receptors might enhance
nuclear localisation of calreticulin. Dexamethasone treatment of
LM(TK
3
) cells doubled the amount of nuclear GFP-CRT, but
did not affect the localisation of a GFP-CRT fusion in which the
glucocorticoid receptor-binding N-domain of calreticulin had
been deleted. Thus, despite ER targeting and retention signals,
calreticulin is also located within the nucleus where its presence
increases due to its interaction with glucocorticoid receptors.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
In addition to its apparent major role as a calcium storage
protein within the lumen of the ER, calreticulin has been
proposed to have functions that necessitate its presence at
cellular locations other than the ER [1]. These include the
nucleus, where it regulates steroid-inducible gene expression
[2^4], and the cytosol, where it is involved in the control of
cell adhesion via interaction with the K subunits of integrins
[5]. The presence of calreticulin in the nucleus has been dem-
onstrated by both immunocytochemistry [6,7], and sub-cellu-
lar fractionation [8]. However, due to staining and ¢xation
artefacts inherent in the immunocytochemical approaches
[9], the possibility of contamination in sub-cellular fractiona-
tion, and the indirect nature of the functional studies, the
presence of calreticulin in the nucleus remains contentious.
Indeed, it has been suggested that the constitutive presence
of nuclear calreticulin may be artefactual [10]. Furthermore,
although there is a putative nuclear localisation signal
(PPKKIKDPD) in calreticulin [11], it remains unclear how
a protein containing an N-terminal ER-targeting signal and
a C-terminal KDEL salvage sequence [12] escapes ER reten-
tion and translocates to the nucleus. One possibility is that a
nuclear-speci¢c isoform exists, but although a number of cal-
reticulin isoforms have been found in bovine tissues, all have
both the ER targeting and retention signals [13].
We have addressed these problems by engineering fusions
of calreticulin and GFP [14] that have allowed us to investi-
gate directly calreticulin distribution in live cells. The data
show that, despite ER targeting and retention signals, calreti-
culin is also located within the nucleus. Furthermore, its pres-
ence within the organelle is enhanced as a result of the pro-
tein's interaction with glucocorticoid receptors.
2. Materials and methods
2.1. Materials
Plasticware and tissue culture reagents were from GibcoBRL (Pais-
ley, UK). Cell lines were obtained from the European Tissue Culture
Collection (Porton Down, UK). Restriction and modifying enzymes
were purchased from Promega (Southampton, UK) and Bioline (Lon-
don, UK). General laboratory chemicals were from Sigma (Poole,
UK), or Fisons (Loughborough, UK). The anti-GFP antibody was
obtained from Clontech (Palo Alto, USA), and the Cy3 goat anti-
rabbit IgG came from Zymed (San Francisco, USA).
2.2. Engineering of GFP fusions and cloning
A cDNA containing the whole of the calreticulin protein-coding
sequence was generated from HL60 mRNA by reverse transcrip-
tion-polymerase chain reaction (RT-PCR). Primers were derived
from the published sequence [15] (¢gures in parentheses refer to the
sequence positions given therein):
Both the wild-type (wt) GFP [14] and its S65T variant [16], which
forms its £uorescent chromophore more rapidly at 37³C, and has an
excitation wavelength more suitable for FITC ¢lter sets, were ob-
tained from Clontech, Palo Alto, USA. These were used in a two-
stage PCR strategy [17] to generate GFP-CRT chimeric cDNA con-
structs. The following constructs were engineered using the primers
indicated:
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Primer 1: calreticulin forward primer (356)
5
0
GCCGCTGCCGGGAGGGTGGTTTT
3
0
Primer 2: calreticulin reverse primer (+1432)
5
0
AAGGGCGGGGAGGGGGTGGGGG
3
0
ER-GFP: CRT ER signal peptide-GFP(wt/S65T)+KDEL
Primer 3: part of calreticulin signal peptide+GFP forward primer
5
0
gtgccgctgctgctcggcctcctcggcctggccgtcgccaGTAAAGA-
GAAGAACTT
3
0
Primer 4: GFP reverse primer+kdel
5
0
ttacagctcatccttTTTGTATAGTTCATCCAT
3
0
GFP-CRT: CRT ER signal peptide/GFP/CRT(no signal peptide+
KDEL)
Primer 3: part of calreticulin signal peptide+GFP forward primer
(as above)
Primer 5: reverse primer for GFP-calreticulin fusion site
5
0
gtagacggcgggctcTTTGTATAGTTCATC
3
0
Primer 6: forward primer for GFP-calreticulin fusion site
5
0
GATGAACTATACAAAgagcccgccgtctac
3
0
Primer 2: calreticulin reverse primer (+1432) (as above)
Primer 7: to add the N-terminus of calreticulin signal sequence
to both constructs:
5
0
CCCGCCATGCTGCTGCTATCCGTGCCGCTGCT-
GCTC
3
0
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A fusion was also generated in which the N-domain (amino acids
1^180) of the calreticulin protein [18] was deleted:
In all cases, the PCR generated products were cloned into pCR3, a
TA cloning vector with a CMV immediate-early promoter (Invitro-
gen, The Netherlands).
2.3. Cell culture and transfection methods
Cell lines were grown in Dulbecco's Modi¢ed Eagle Medium
(DMEM) without phenol red, supplemented with 10% foetal calf se-
rum, 2 mM L-glutamine, 100 Wg/ml penicillin, 100 Wg/ml streptomycin
and 100 Wg/ml amphotericin B. Cells were transfected using the cal-
cium phosphate method. Medium was changed 24 h post transfection
and 24 h later cells were re-seeded at 2U10
4
for COS7 cells, and
6U10
4
for both HeLa and LM(TK
3
) cells in the centre of a 22U22
mm glass cover slip.
In experiments where dexamethasone was added, cells were washed
in serum-free medium and incubated with 1 WM dexamethasone for 30
min. The relatively short incubation time has been shown to be su¤-
cient for maximal nuclear translocation of the glucocorticoid receptor
in response to dexamethasone [19,20].
2.4. Immunocytochemistry
Cells were ¢xed with 2% paraformaldehyde, 0.1% glutaraldehyde
for 15 min at room temperature. After washing with phosphate-buf-
fered saline (PBS) pH 7.4, the cells were permeabilised with 0.1%
Triton X-100/0.1 M lysine. Following incubation with 10% (v/v)
pre-immune goat serum/PBS for 1 h, cells were incubated overnight
at 4³C with a rabbit anti-GFP antibody. Detection was by a Cy 3
conjugated secondary antibody. The cover slips were mounted with
Vectashield (Vector Laboratories, Peterborough, UK)
2.5. Observation and quanti¢cation of GFP £uorescence in live cells
Cells were observed using excitation (488 nm), and emission (515
nm) wavelengths for FITC, using a Leica TCS 4d confocal laser
scanning microscope. The objective, lens, pinhole diameter, and sen-
sitivity of detector were constant for all sections. A series of sections
through each £uorescent cell was performed, with the section through
the centre of the nucleus chosen for analysis. Photometric analysis of
digitised confocal sections was performed using Photek image analysis
software (Photek, St. Leonards-on-Sea, UK). In order to determine
the degree of nuclear £uorescence, and account for di¡erences in cell
size and relative £uorescence intensity, areas corresponding to the
nucleus and the whole cell were encircled, and the ratio of nuclear
to whole cell £uorescence determined [21].
3. Results
3.1. The ER-targeted GFP S65T variant £uoresces in the
ER lumen.
Since calreticulin is primarily an ER lumenal protein, we
¢rst determined whether GFP £uorescence could be detected
within the ER lumen of COS7 cells, employing a targeting
strategy involving the use of the calreticulin N-terminal signal
peptide and the C-terminal KDEL salvage sequence [22]. Im-
munolocalisation with an anti-GFP antibody con¢rmed that
both wt and S65T ER-targeted GFP constructs were ex-
pressed and localised in the ER. However, GFP £uorescence
was only observed with the S65T variant (data not shown).
No nuclear £uorescence was visible with the S65T ER-GFP
fusion (Fig. 1a), and photometric analysis showed that the
ratio of nuclear to whole cell £uorescence was less than
0.001.
3.2. GFP-CRT localises predominantly to the ER, but is also
found in the nucleus
Having demonstrated that the S65T variant £uoresces with-
in the ER lumen, it was used to generate a fusion (GFP-CRT)
with calreticulin by inserting GFP between the calreticulin N-
terminal signal peptide and the remainder of the protein. In
contrast to ER-GFP (Fig. 1a), £uorescence from the GFP-
CRT fusion was visible in the nucleus of all the cell types
(Fig. 1b,c, and Table 1). Photometric analysis showed that
the ratio of nuclear to whole cell £uorescence in COS7 cells,
which displayed the least amount of GFP-CRT nuclear £uo-
rescence, was at least 4 times higher than the level observed
for ER-GFP.
In order to con¢rm that the presence of the GFP-calreticu-
lin fusion within the nucleus was not due to mis-targeting as a
result of its overexpression, we performed western blotting of
cell lysates of GFP-CRT transfected cells using an anti-calre-
ticulin antibody that we raised against the whole recombinant
protein. In addition to detecting endogenous calreticulin,
there was a single band of the expected size for the correctly
processed GFP-CRT fusion, i.e. the signal peptide had been
e¤ciently cleaved (data not shown). A previous study has
shown that where calreticulin was overexpressed 50^100-fold
per cell its distribution was una¡ected [23]. Thus, we infer that
the nuclear localisation of the GFP-CRT fusion does not arise
from its mis-targeting due to saturation of the ER transloca-
tion machinery, but occurs as a result of tra¤cking due to
sequence(s) present within the calreticulin moiety of the chi-
mera. However, an alternative explanation for our observa-
tions was suggested by a recent report showing that invagina-
tions of the ER extend into, and through the nucleus [24],
raising the possibility that the GFP-CRT fusion protein is
present in such invaginations and not the nucleus per se. To
exclude this possibility, confocal sections of the transfected
cells were taken across all planes showing that the nuclear
calreticulin detected was within the nucleoplasm and not in-
vaginating ER cisternae.
3.3. Nuclear localisation of calreticulin is enhanced by the
interaction of its N-domain with glucocorticoid receptors
Photometric analysis showed that the degree of GFP-CRT
nuclear £uorescence varied considerably between the cell
types, with 10-fold and 6-fold less nuclear GFP-CRT in
COS7 cells than in LM(TK
3
) cells and HeLa cells, respec-
tively (Table 1). Unlike COS7 cells, both HeLa cells and
LM(TK
3
) cells possess glucocorticoid receptors with which
calreticulin interacts [2,3]. This suggested that the greater level
of nuclear GFP-CRT in these cells, compared to COS7 cells,
might be due to this interaction, resulting in its co-transloca-
tion to the nucleus with glucocorticoid receptors. Therefore,
we determined whether GFP-CRT nuclear localisation in
HeLa cells and LM(TK
3
) cells was a¡ected by treatment
with the synthetic glucocorticoid dexamethasone which acti-
vates the glucocorticoid receptors causing them to translocate
to the nucleus [25]. This treatment resulted in a 2-fold increase
in nuclear £uorescence of GFP-CRT transfected in LM(TK
3
)
cells, but, in contrast, had no e¡ect in similarly treated HeLa
cells or COS7 cells (Table 1). The distribution of the ER-GFP
construct was una¡ected by dexamethasone. These observa-
tions are in accordance with previous reports that only in
certain glucocorticoid receptor containing cells, including
LM(TK
3
) cells, but not HeLa cells, can dexamethasone-
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GFP-
CRT(vN):
CRT ER signal peptide/GFP/CRTvN (no signal pep-
tide+KDEL)
Primer 8: forward primer for GFP and calreticulin(vN) fusion.
5
0
ttccaaggagccggaTTTGTATAGTTCATC
3
0
Primer 9: reverse primer for GFP and calreticulin(vN) fusion.
5
0
GATGAACTATACAAAtccggctccttggaa
3
0
H.Ll. Roderick et al./FEBS Letters 405 (1997) 181^185182
stimulated nuclear translocation of endogenous glucocorticoid
receptors be detected [20,25,26]. In order to substantiate fur-
ther the involvement of glucocorticoid receptors in the nuclear
localisation of calreticulin, we performed similar experiments
in LM(TK
3
) cells utilising a GFP-CRT construct in which the
glucocorticoid receptor-binding N-domain of the calreticulin
protein had been deleted. Again, this showed essentially an
ER distribution, but with £uorescence also present in the nu-
cleus. However, this nuclear £uorescence was 5.7-fold lower
than that of the full-length GFP-CRT construct, and was
una¡ected by dexamethasone treatment (Fig. 1c,d, and Table
1).
Thus, we conclude that, despite ER targeting and retention
signals, calreticulin is found within the nucleus. Furthermore,
the degree of nuclear localisation of calreticulin appears to be
dependent on the presence of glucocorticoid receptors infer-
ring that the protein is able to enter the nucleus in association
with such receptors.
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Fig. 1. Fluorescence of ER-GFP and GFP-CRT fusions in COS7 and LM(TK
3
) cells. Typical confocal sections of live transfected cells ob-
served under U1000 initial magni¢cation. GFP £uorescence was detected using FITC excitation and emission wavelengths. None of the cells il-
lustrated had been treated with dexamethasone. (a) ER-GFP £uorescence in COS7 cells showing a typical ER network with no £uorescence
visible in the nucleus. (b) GFP-CRT £uorescence in COS7 cells. In addition to the expected ER distribution, there is also £uorescence within
the nucleus unlike the ER-GFP fusion shown in panel (a). (c) GFP-CRT £uorescence in LM(TK
3
) cells. As with COS7 cells, there is again £u-
orescence within the nucleus, calculated by photometry to be 10-fold greater than that in COS7 cells (see Table 1). (d) GFP-CRT(vN) £uores-
cence in LM(TK
3
) cells. Fluorescence is again visible within the nucleus, but is 5.7-fold lower than that for the full-length GFP-CRT fusion,
demonstrating the role of the calreticulin N-domain in its nuclear localisation.
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4. Discussion
Several of the functions ascribed to calreticulin necessitate
that it is located within the nucleus where its presence has
been contentious. Employing GFP as an in vivo reporter of
calreticulin cellular distribution, we have demonstrated con-
clusively that calreticulin is found within the nucleus in addi-
tion to its expected ER localisation. It has been suggested that
there may be a nuclear-speci¢c isoform of the protein, but,
like the endogenous protein, our fusions possess an N-termi-
nal ER targeting sequence and a C-terminal retention signal
which may argue against the existence of such an isoform.
Our data showed low levels of calreticulin within the nucleus
of all the cell types we studied, but there was much less in
COS7 cells than either LM(TK
3
) or HeLa cells. It may be
that calreticulin is totally absent from the nucleus in some
types of cells, although it is possible that its levels are too
low to be detected by antibody-dependent techniques.
A number of crucial questions arise concerning the mecha-
nism and route by which ER-targeted calreticulin locates to
the nucleus. The protein has a putative nuclear localisation
signal (NLS) in its P-domain [1]. It has been shown that in-
jection of FITC-labelled calreticulin into the cytosol of ¢bro-
blasts leads to transient nuclear localisation of the protein
[27], implying a route into the nucleus from the cytosol, where
calreticulin has been detected [10]. Our data provide strong
evidence that calreticulin can also locate to the nucleus from
the cytosol by virtue of its interaction with glucocorticoid
receptors. First, there were higher levels of nuclear calreticulin
in LM(TK
3
) and HeLa cells, which contain glucocorticoid
receptors, than in COS7 cells which lack them. Secondly,
the deletion of the glucocorticoid receptor-binding N-domain
of calreticulin from our fusion reduced its levels within the
nucleus of LM(TK
3
) cells to those seen in COS7 cells and,
unlike the wild-type calreticulin fusion, these did not increase
in response to dexamethasone treatment. Ligand binding
causes dissociation of glucocorticoid receptors from their cy-
tosolic multi-protein complexes resulting in their translocation
to the nucleus [28]. The e¡ect of ligand stimulation upon the
localisation of endogenous glucocorticoid receptors has been
studied in a variety of cell types showing that discernible
nuclear translocation is detected only in certain cell types,
including LM(TK
3
) cells, but not others, such as HeLa
[20,25,26]. These observations might explain why dexametha-
sone had no e¡ect upon nuclear calreticulin in HeLa cells, but
appeared to increase its levels in LM(TK
3
) cells. The appear-
ance of calreticulin in the nucleus prior to dexamethasone
stimulation might be attributable to the presence of glucocor-
ticoid receptors within the nucleus of unstimulated cells
[21,26], as well as the e¡ect of the NLS which presumably
accounts for the presence of calreticulin in the nucleus of
COS7 cells. We are currently mutating this signal and other
regions of the calreticulin protein to investigate their contri-
bution to its nuclear localisation. It also remains to be re-
solved how calreticulin locates to the cytosol from the ER.
The conclusive demonstration that calreticulin is in the nu-
cleus is important for the roles that have been attributed to
the protein. It can modulate steroid-inducible gene expression
[2,3] and it might also contribute to the control of nuclear
calcium signalling. Furthermore, it has recently been shown
that irradiation of radioresistant squamous carcinoma epithe-
lial cells caused translocation of calreticulin into the nucleus
[8]. Thus, it may be that calreticulin within the nucleus is
involved in controlling important cellular processes such as
di¡erentiation, cell death, and apoptosis.
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